{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=7", "query": { "intervention": "matched placebo", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 7009, "total_pages": 701, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+placebo&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T09:34:16.319Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02616315", "title": "Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Weight Regain Post Bariatric Surgery" ], "interventions": [ { "name": "Naltrexone HCl/Bupropion HCl Placebo", "type": "DRUG" }, { "name": "Naltrexone HCl/Bupropion HCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2016-02", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2016-04-08", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 2, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616315" }, { "nct_id": "NCT01082640", "title": "Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Impairment" ], "interventions": [ { "name": "Febuxostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2010-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-09-25", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Sierra Vista", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082640" }, { "nct_id": "NCT01414920", "title": "Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TAK-875", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "TAK-875 and Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 368, "start_date": "2011-08", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Brimingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Green Valley", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414920" }, { "nct_id": "NCT01590459", "title": "24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "VX-509", "type": "DRUG" }, { "name": "VX-509 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 359, "start_date": "2012-04", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01590459" }, { "nct_id": "NCT03126318", "title": "A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Kidney Diseases" ], "interventions": [ { "name": "COR-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 32, "start_date": "2017-05-19", "completion_date": "2019-12-19", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126318" }, { "nct_id": "NCT07355218", "title": "A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systematic Lupus Erythematosus", "Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "Enpatoran", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 202, "start_date": "2026-04-01", "completion_date": "2029-05-25", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 14, "location_summary": "Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more", "locations": [ { "city": "Upland", "state": "California" }, { "city": "DeBary", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07355218" }, { "nct_id": "NCT03986086", "title": "MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "MPH966", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nelson Chao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2021-09", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2020-03-20", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03986086" }, { "nct_id": "NCT01844505", "title": "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable or Metastatic Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Placebo for Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo for Ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 945, "start_date": "2013-06-11", "completion_date": "2024-04-19", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 46, "location_summary": "Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 35 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844505" }, { "nct_id": "NCT01896531", "title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2013-08-14", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896531" }, { "nct_id": "NCT02243202", "title": "Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Phentermine", "type": "DRUG" }, { "name": "Matching Placebo to Canagliflozin", "type": "DRUG" }, { "name": "Matching Placebo to Phentermine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 335, "start_date": "2014-09", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-06", "last_synced_at": "2026-10-18T09:34:16.319Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02243202" } ] }